We recently published a list of 10 Firms Kick Off Shortened Trading Week With Impressive Gains. In this article, we are going ...

Below is Validea's guru fundamental report for MODERNA INC (MRNA). Of the 22 guru strategies we follow, MRNA rates highest using our Value Investor model based on the published strategy of ...

We recently published a list of Five Chinese Firms Dominate Friday’s Top 10 Gainers. In this article, we are going to take a look at where Moderna Inc. (NASDAQ:MRNA) stands against the other friday’s ...

Q4 2024 Earnings Call Transcript February 14, 2025 Moderna, Inc. misses on earnings expectations. Reported EPS is $-2.91 EPS, ...

While the details surrounding the new virus are still unfolding, the market's reaction reflects concern over the potential ...

Barclays downgraded shares of Moderna (NASDAQ:MRNA – Free Report) from an overweight rating to an equal weight rating in a report published on Tuesday, Ratings reports. The firm currently has $45.00 ...

The article " Moderna: A Generational Opportunity for Investors in 2025 " first appeared on MarketBeat.

CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company specializing in mRNA-based therapies and vaccines with a market ...

The stock market saw concerning drops on Friday, but shares in Pfizer and Moderna were shockingly on the rise.

Moderna, Inc. (NASDAQ:MRNA – Get Free Report) was the recipient of unusually large options trading on Tuesday. Stock investors bought 179,268 call options on the company. This represents an increase ...

Moderna (NASDAQ:MRNA – Get Free Report)‘s stock had its “sector perform” rating reaffirmed by stock analysts at Royal Bank of Canada in a research report issued on Tuesday,Benzinga reports. They ...

Bernstein analyst Courtney Breen maintained a Hold rating on Moderna (MRNA – Research Report) on February 14 and set a price target of $45.00.